<code id='11D646F909'></code><style id='11D646F909'></style>
    • <acronym id='11D646F909'></acronym>
      <center id='11D646F909'><center id='11D646F909'><tfoot id='11D646F909'></tfoot></center><abbr id='11D646F909'><dir id='11D646F909'><tfoot id='11D646F909'></tfoot><noframes id='11D646F909'>

    • <optgroup id='11D646F909'><strike id='11D646F909'><sup id='11D646F909'></sup></strike><code id='11D646F909'></code></optgroup>
        1. <b id='11D646F909'><label id='11D646F909'><select id='11D646F909'><dt id='11D646F909'><span id='11D646F909'></span></dt></select></label></b><u id='11D646F909'></u>
          <i id='11D646F909'><strike id='11D646F909'><tt id='11D646F909'><pre id='11D646F909'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:focus    Page View:2
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In